Free Trial

2,070 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by Alps Advisors Inc.

Quest Diagnostics logo with Medical background

Alps Advisors Inc. acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,070 shares of the medical research company's stock, valued at approximately $350,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DGX. Allworth Financial LP increased its stake in Quest Diagnostics by 26.0% in the 1st quarter. Allworth Financial LP now owns 1,321 shares of the medical research company's stock valued at $232,000 after buying an additional 273 shares during the period. Aurdan Capital Management LLC purchased a new stake in shares of Quest Diagnostics in the 1st quarter worth about $1,285,000. Nisa Investment Advisors LLC boosted its position in shares of Quest Diagnostics by 2.7% in the 1st quarter. Nisa Investment Advisors LLC now owns 10,837 shares of the medical research company's stock worth $1,834,000 after buying an additional 282 shares in the last quarter. Linden Thomas Advisory Services LLC raised its stake in Quest Diagnostics by 0.6% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 11,513 shares of the medical research company's stock valued at $1,948,000 after purchasing an additional 63 shares during the last quarter. Finally, Greenleaf Trust raised its stake in Quest Diagnostics by 3.9% in the 1st quarter. Greenleaf Trust now owns 3,129 shares of the medical research company's stock valued at $529,000 after purchasing an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company's stock.

Insider Buying and Selling

In other news, SVP Mark E. Delaney sold 874 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $175.72, for a total value of $153,579.28. Following the transaction, the senior vice president directly owned 8,372 shares in the company, valued at $1,471,127.84. This trade represents a 9.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.16% of the company's stock.

Analyst Ratings Changes

DGX has been the subject of a number of analyst reports. Robert W. Baird upped their price target on Quest Diagnostics from $191.00 to $194.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Evercore ISI raised their price objective on Quest Diagnostics from $175.00 to $180.00 and gave the stock an "in-line" rating in a research note on Wednesday, April 23rd. Redburn Atlantic started coverage on Quest Diagnostics in a research note on Wednesday, April 2nd. They set a "buy" rating and a $195.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on Quest Diagnostics from $180.00 to $190.00 and gave the company a "neutral" rating in a research note on Tuesday, May 6th. Finally, Mizuho raised their price target on Quest Diagnostics from $178.00 to $189.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Quest Diagnostics has a consensus rating of "Moderate Buy" and a consensus target price of $186.07.

View Our Latest Report on DGX

Quest Diagnostics Trading Down 0.8%

Shares of Quest Diagnostics stock traded down $1.39 on Friday, hitting $166.79. 1,557,274 shares of the company's stock traded hands, compared to its average volume of 1,003,691. Quest Diagnostics Incorporated has a one year low of $137.71 and a one year high of $182.38. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.44 and a quick ratio of 1.31. The company has a fifty day moving average of $174.95 and a two-hundred day moving average of $169.08. The company has a market capitalization of $18.62 billion, a price-to-earnings ratio of 21.09, a price-to-earnings-growth ratio of 2.33 and a beta of 0.49.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.11% and a net margin of 8.81%. The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.63 billion. As a group, sell-side analysts expect that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 21st. Shareholders of record on Monday, July 7th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, July 7th. This represents a $3.20 annualized dividend and a yield of 1.92%. Quest Diagnostics's dividend payout ratio is 40.46%.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Articles

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Should You Invest $1,000 in Quest Diagnostics Right Now?

Before you consider Quest Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.

While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines